GUTS — Fractyl Health, Inc. Common Stock

Summary of Fractyl Health Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Research and Development Expenses: $16.5 million, down from $20.3 million in Q4 2024, attributed to strategic reprioritization and reduced costs from pausing the REVITALIZE-1 study.
• SG&A Expenses: Increased to $6.8 million from $4.9 million in Q4 2024, primarily due to underwriters' commissions from an August 2025 financing.
• Net Loss: Reported at $43.7 million, up from $25 million in Q4 2024. The increase included a non-cash accounting change of $20.2 million related to warrant liabilities.
• Adjusted EBITDA: Negative $21.2 million, slightly improved from negative $22.1 million in Q4 2024.
• Cash Position: Approximately $81.5 million as of December 31, 2025, expected to fund operations into early 2027.

2. Strategic Updates and Business Highlights

• Revita Development: The endoscopic procedure Revita aims to maintain weight loss after discontinuation of GLP-1 therapy. Positive feedback from the FDA on the filing strategy was received, indicating a potential De Novo classification.
• Pivotal Study: The REMAIN-1 pivotal study is set to deliver top-line 6-month data in early Q4 2026, with a focus on ablation length and patient selection showing promising results.
• Commercial Opportunity: The growing population on GLP-1 drugs presents a significant market for Revita, with expectations of over 30 million users in the coming years. The company is preparing for a potential commercial launch following FDA clearance.
• Rejuva Platform: The smart GLP-1 platform targeting long-term metabolic remission is advancing, with clinical trial applications submitted in the EU and Australia.

3. Forward Guidance and Outlook

• Upcoming Milestones: Key data releases expected in Q2 and Q3 2026, including 1-year data from the REVEAL-1 study and REMAIN-1 Midpoint Cohort. The pivotal study is anticipated to provide critical data in early Q4 2026.
• De Novo Submission: Planned for late Q4 2026, with the potential for a Category III CPT code application to be filed in June 2026.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The significant rise in net loss raises concerns about financial sustainability, although much of it is attributed to non-cash accounting changes.
• Clinical Data Variability: Initial data from the Midpoint Cohort showed less robust results than expected, leading to a need for further analysis and refinement of procedural standards.
• Regulatory Risks: While FDA feedback has been positive, the success of the De Novo submission is contingent on meeting safety and efficacy standards, which remain a risk.

5. Notable Q&A Insights

• Ablation Length: The optimal ablation length for efficacy is now established at 16 centimeters, which will be standardized in training for physicians.
• Training for Physicians: Training to achieve adequate ablation lengths is efficient, requiring only a few cases for physicians to become proficient.
• Regulatory Submission Process: The De Novo submission will involve multiple packages, including clinical data, and the efficacy threshold differs from PMA requirements.
• Payer Discussions: Anticipated to commence late 2026, leveraging comprehensive clinical data to support reimbursement discussions.

Overall, Fractyl Health is positioned for potential growth with its innovative Revita procedure, although it faces financial challenges and must navigate regulatory hurdles effectively. The upcoming data releases and strategic initiatives will be critical in shaping its future trajectory.